- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04187443
MS-553 in Diabetic Retinopathy Patients With Central Involved Macular Edema
March 13, 2023 updated by: Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.
A Multicenter, Open-label, Dose Escalation Study Assessing the Safety and Treatment Effects of MS-553 in Diabetic Retinopathy Patients With Central Involved Macular Edema
This is an open label dose-escalation study to evaluate the safety and treatment benefits of MS-553 in treatment-naive diabetic retinopathy patients with central involved macular edema.
Fifteen subjects with diabetic macular edema will be enrolled into each of three dose cohorts and will receive oral administration of MS-553 for 8 weeks.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
45
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Shanghai, China, 200080
- Recruiting
- Shanghai General Hospital
-
-
Hunan
-
Changsha, Hunan, China
- Recruiting
- The Second Xiangya Hospital of Central South University
-
-
Sichuan
-
Chengdu, Sichuan, China
- Recruiting
- West China Hospital of Sichuan University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Diagnosis of diabetes mellitus (type 1 or type 2) according to ADA or WHO diabetic diagnosis criteria
- Subject has the ability to follow the study instructions and is likely to complete all required study procedures and visits;
- All males and females must consent to pregnancy prevention during the study and qualified measures of birth control. All females of childbearing potential must consent to a pregnancy test before entering the study.
- Presence of central involved macular edema associated with diabetic retinopathy, i.e. diabetic macular edema (DME), as assessed by spectral domain optical coherence tomography (sd-OCT) of the central retina subfield thickness (CRT) at the Screening Visit (Centration must be confirmed by Investigators with signatures);
- Best Corrected Visual Acuity (BCVA) score ≥ 34 letters (approximately 20/200 to 20/20 Snellen equivalent or better) using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity protocol, and assessed at the Screening Visit Visual acuity (VA);
- Confirmation by the investigator that laser photocoagulation and anti-VEGF treatments are either declined by the patients or not needed and can be withheld for at least 3 months after the Screening Visit;
- Ocular media and pupil dilation adequate to permit good quality retinal imaging as assessed at Screening Visit.
Exclusion Criteria:
- Subjects with unstable metabolic or blood pressure control
- Subject with emaciation or obesity at Screening Visit: body mass index (BMI) <18.5kg/m2 or >28kg/m2
- Current use or likely need for medications know to be toxic to the lens, retina or optic nerve, including Deferoxamine, Chloroquine / hydroxychloroquine (Plaquenil), Tamoxifen, Phenothiazines and Ethambutol -
- History of myocardial infarction or other cardiac event requiring hospitalization (unstable angina pectoris, etc.), cerebrovascular accident, transient ischemic attack, treatment for acute congestive heart failure or any arrhythmia within 4-months prior to Screening Visit;
- Any situation that may in the opinion of the investigator preclude the safe administration of the study medication, adherence to the scheduled study visits, safe participation in the study or affect the results of the study as assessed at Screening Visit;
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MS-553 low dose
low dose of MS-553 taken orally
|
MS-553
|
Experimental: MS-553 mid dose
mid dose of MS-553 taken orally
|
MS-553
|
Experimental: MS-553 high dose
high dose of MS-553 taken orally
|
MS-553
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Treatment-emergent adverse events
Time Frame: Baseline to Day 56
|
Baseline to Day 56
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Mean change in the central retina subfield thickness (CRT)
Time Frame: Baseline to Day 56
|
Baseline to Day 56
|
Mean change in the retinal volume
Time Frame: Baseline to Day 56
|
Baseline to Day 56
|
Proportion of patients with >20% reduction in CRT
Time Frame: Baseline to Day 56
|
Baseline to Day 56
|
Proportion of patients with resolution of central involved macular edema
Time Frame: Baseline to Day 56
|
Baseline to Day 56
|
Average mean change in best corrected visual acuity
Time Frame: Baseline to Day 56
|
Baseline to Day 56
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 2, 2020
Primary Completion (Anticipated)
December 31, 2023
Study Completion (Anticipated)
January 31, 2024
Study Registration Dates
First Submitted
December 3, 2019
First Submitted That Met QC Criteria
December 3, 2019
First Posted (Actual)
December 5, 2019
Study Record Updates
Last Update Posted (Actual)
March 15, 2023
Last Update Submitted That Met QC Criteria
March 13, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2019-001-CN
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Retinopathy
-
Retina Institute of HawaiiUnknownDiabetic Macular Edema | Proliferative Diabetic Retinopathy | Severe Nonproliferative Diabetic Retinopathy | Mild Nonproliferative Diabetic Retinopathy | Moderate Nonproliferative Diabetic RetinopathyUnited States
-
University of CataniaUnknownProliferative Diabetic Retinopathy | Non Proliferative Diabetic RetinopathyItaly
-
Asociación para Evitar la Ceguera en MéxicoCompletedProliferative Diabetic Retinopathy | Severe Nonproliferative | Active Photocoagulated Diabetic RetinopathyMexico
-
Asociación para Evitar la Ceguera en MéxicoUnknownProliferative Diabetic Retinopathy | Non Proliferative Diabetic RetinopathyMexico
-
Valo Health, Inc.RecruitingProliferative Diabetic Retinopathy | Non-proliferative Diabetic RetinopathyUnited States
-
Asociación para Evitar la Ceguera en MéxicoUnknownNon Proliferative Diabetic Retinopathy. | Proliferative Diabetic Retinopathy.Mexico
-
AEYE Health IncA. Stein Regulatory Affairs Consulting Ltd.RecruitingDiabetic Mellitus | Diabetic Retinopathy, DRUnited States
-
Ocuphire Pharma, Inc.CompletedDiabetic Retinopathy | Diabetic Macular Edema | NPDR - Non Proliferative Diabetic Retinopathy | PDR - Proliferative Diabetic RetinopathyUnited States
-
King Khaled Eye Specialist HospitalCompletedDiabetic Macular Edema | Proliferative Diabetic Retinopathy | Non-proliferative Diabetic RetinopathySaudi Arabia
-
Retina Macula InstituteAllerganCompletedDiabetic Macular Edema | Proliferative Diabetic Retinopathy | Non-proliferative Diabetic RetinopathyUnited States
Clinical Trials on MS-553
-
MingSight Pharmaceuticals, IncShenzhen MingSight Relin Pharmaceutical Co., LtdRecruitingChronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | Mantle Cell Lymphoma (MCL) | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Relapsed or Refractory B-cell Lymphoma | Marginal Zone Lymphoma (MZL)China
-
Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.RecruitingSmall Lymphocytic Lymphoma | Lymphocytic LeukemiaChina
-
MingSight Pharmaceuticals Pty LimitedCompletedSafety and PK in Healthy VolunteersAustralia
-
AmgenWithdrawnRelapsed/Refractory Acute Myeloid LeukemiaUnited States
-
MingSight Pharmaceuticals, IncRecruitingChronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Aggressive LymphomaUnited States
-
University of Illinois at ChicagoCongressionally Directed Medical Research ProgramsRecruitingMultiple Sclerosis | Major Depressive DisorderUnited States
-
University Hospital, CaenRecruiting
-
University of Erlangen-Nürnberg Medical SchoolUnknownCoagulation Protein Disorders | Preterm Birth | Coagulation Disorder NeonatalGermany